Advanced searches left 3/3

Cyclophosphamide - Crossref

Summarized by Plex Scholar
Last Updated: 27 June 2022

* If you want to update the article please login/register

Abstract P6-15-09: Final results of weekly (w) neoadjuvant carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts): A BSMO breast cancer task force phase II study

Abstract Introduction: The prognosis of early TNBC remains inferior to that of other breast cancer subtypes. In TNBC pts, the Neoadjuvant platinum added to the taxanes-anthracycline regimen has been shown to have the ability to enhance pathologic complete response and survival. In an open-label phase II research in stage II/III TNBC pts, Aim: To publish the final findings of the investigation into the pCR rate and the toxicity of adding weekly Cp to P and dose dense EC on the pCR rate. Patients and methods: In the BSMO research, sixty three pts were issued dd P covalent with Cp for 12 weeks, which was added to bi-weekly E and C for four cycles, as well as surgery and radiotherapy. A correlative analysis of germline mutations in HRD genes is ongoing. To find a pCR rate of > or=47%, the target sample size was 63 patients with 80% power, with a 80% chance of detecting a pCR rate of > or=47%. In ten pts, Thrombocytopenia G3/4 was observed. Only four out of every four pts developed grade 3 peripheral neuropathy, and peripheral neuropathy was present in only four pts. Conclusion: The addition of weekly carboplatinum to neoadjuvant paclitaxel and ddEC is a good idea, and a pCR rate in the breast and axilla is expected, which is comparable to the ones obtained with the CALBG 40603 trial's similar 3-week carboplatinum arm. In the CALGB40603 trial, the fetidine neutropenia rate was higher than the 3-week carboplatin arm, but this was mostly during the EC portion, although other toxicities are similar. In:: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, Texas; 2017 Dec 5-9; In:: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9.

Source link: https://doi.org/10.1158/1538-7445.sabcs17-p6-15-09


Abstract P6-15-06: SOLTI-0702 CAPRICE: Final results of a phase II study of pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as neoadjuvant chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: 5-year overall survival disease free survival and late cardiac safety

Abstract Background: Anthracycline and taxane-based chemotherapy is the most common treatment for high-risk breast cancer. Pegylated liposomal doxorubicin has similar performance but with a lower cardiotoxicity profile than traditional anthracyclines. In this group of patients, we performed a phase II trial to determine the efficiency and safety of a neoadjuvant chemotherapy based on PLD and paclitaxel. Methods: Fifty patients with stage II and III breast cancer, as well as one risk factor for developing cardiotoxicity, were included in this study. Every 6 months, every 12 months year 4-6 of follow-up, including 5-year DFS, 5year OS, and cardiac safety determined by a decrease in left ventricular ejection fraction, electrocardiogram, and a cardiac questionnaire conducted every 3 months during the first year. PLD plus CPM cycles were completed by forty-eight patients, with only 26 patients able to complete the 12 weeks of PTX. After 60 months, the 5-year OS was 56% and the 5-year DFS was 54. 3 [95% CI: 38. 3-67. 9]]. No significant decline in LVEF was seen during 5-year OS; however, mean baseline LVEF was 66. 6 and mean LVEF after 60 months was 66]. PLD was followed by PTX as NC was safe in a vulnerable population of patients who were not candidates for conventional doxorubicin. In elderly patients with predominant TN tumors were similar to the ones described in the literature, 5 year DFS and 5 year OS were similar. In:: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX; Proceedings of the San Antonio Breast Cancer Symposium; 2017 Dec 5-9.

Source link: https://doi.org/10.1158/1538-7445.sabcs17-p6-15-06


Abstract P6-14-04: Is fat mass more effective than body mass index (BMI) to predict toxicity in early breast cancer patients treated with doxorubicin and cyclophosphamide?

Patients and Methods: We conducted a retrospective cohort study of 207 operated breast cancer women treated with doxorubicin and cyclophosphamide for adjuvant setting between 2007 and 2016. In their charts, patients' demographics, toxicities, body mass, body mass index, and body surface area were evaluated. According to BMI and BSA, there are no differences between grade u22653 toxicity according to BMI, and BSA, but no difference was made in univariate analyses [table 1]; however, statistically significant difference was observed according to fat mass. paraphrasedoutput:BMI 33. 010. 983. 48BMI: Body mass index, BSA: body surface area. BMI 36. 3%-40%036. 89BMI: body mass index, BSA: body surface area. BMI 34. 8% 1. 908-1. 946. 43. 48 For age 2. 141. 360. 638. 46BMI: BMI 3. 668. 395. 450. 453. 90. 68. 47 percent 0. 39. 338. 47. 60 0. 801 In our research, fat mass is more valuable than BSA and BMI for analysis to evaluate the risk of breast cancer patients treated with AC in the adjuvant setting, indicating grade u22653 toxicity for breast cancer patients treated with AC. Is fat mass more effective than body mass index to estimate toxicity in early breast cancer patients treated with doxorubicin and cyclophosphamide? In:: Proceedings of the 2017 San Antonio Breast Cancer Symposium, 2017 Dec 5-9; San Antonio, Texas; In: Proceedings of the 2017 San Antonio Breast Cancer Symposium (2017 Dec 5-9).

Source link: https://doi.org/10.1158/1538-7445.sabcs17-p6-14-04


Abstract OT3-06-04: A randomized phase II study of neoadjuvant panitumumab /carboplatin/paclitaxel (PaCT) versus carboplatin/paclitaxel (CT) followed by adriamycin and cyclophosphamide (AC) for newly diagnosed primary triple-negative inflammatory breast cancer (TNIBC)

Abstract: Primary Objective: To determine the complete response rate in patients with primary TNIBC treated with PaCT in comparison to CT, followed by AC. Background: In triple negative breast cancer and inflammatory breast cancer, the EGFR is overexpressed. Given that EGFR targeted therapy may have a promising role in TNBC and IBC, it could have a promising role in TNBC and IBC. Panitumumab's epidermal growth factor ligands and the transforming growth factor EGFu00e1 binding to EGFR and inhibits tumor formation, and induces tumor formation and eradication of established tumors in murine xenograft tumor models. Panitumumab, a fully humanized anti-EGFR antibody, has been shown to be effective in a breast cancer preclinical model based on human breast cancer cell line MDA-MB-468, which has been shown to overexpress EGFR by both IHC and fluorescence in situ hybridization. Therefore, EGFR-targeted therapy may have a promising role in TNBC and IBC. Statistical Considerations: A sample size of 36 patients per arm will yield 84% power to detect a difference of 0. 4 in the CT arm and 0. 44 in the PaCT arm, with a type I error rate of 10% using a one-sided Z test. Based on historical records, we expect that a PaCT regimen's pCR rate would reach 24% more efficacy than a CT regimen. For newly diagnosed primary triple-negative inflammatory breast cancer (abstract), a randomized phase II study of neoadjuvant panitumab/paclitaxel/calcinaxel/carboplatin/paclitaxel/paclitaxel/paclitaxel versus carboplatin/paclitaxel, adriamycin and cyclophosphamide was published [abstract].

Source link: https://doi.org/10.1158/1538-7445.sabcs17-ot3-06-04


Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

Abstract Background: Adjuvant trastuzumab reduces cancer recurrence and enhances survival in patients with HER2-amplified or overexpressing IBC. A cohort of pts without amplification or IHC overexpression on tissue submitted for central testing was found to include two of the pivotal studies that established the ethicacy of H-based testing at local site laboratories. The primary aim was to see if adding H to chemotherapy regimens of ACu2192WP or TC will promote invasive disease-free survival. Compared to 89. 2% for CT alone, the addition of H to CT resulted in 89. 6% in 5-year IDFS. The RFI was 92. 0% for CT+H in comparison to 92. 2% for CT alone, compared to 92. 2% for CT alone. For CT+H and 93. 5% for CT+H and 93. 5% for CT alone, according to 5-year estimates for DRFI, with 92. 7% for CT+H and 93. 5% for CT+H and 93. 5% for CT+H and 93. 5% for CT+B and 93. 5% for CT+H and 93. 5% for CT+H and 93. 5% for CT+H and 93. 5% for CT+H and 93. In CT+H vs. 96. 2% in CT alone, the addition of H did not change OS significantly with 5-year point estimates of 94. 8% in CT+H vs. 96. 2%. Women in the CT arm experienced Grade 4 or 5 toxicities in comparison to 5. 6% in CT+H. The addition of H to CT did not result in IDFS, RFI, or DRFI in women with non-overexpressing but IHC measurable HER2 IBC. The optimum for H benefit, whether it be HER2 expression or genetic amplification, remains unchanged. In:: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, Texas; 2017 Dec 5-9; In:: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9.

Source link: https://doi.org/10.1158/1538-7445.sabcs17-gs1-02


Abstract GS3-05: Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer – GBG69

Abstract Introduction The GeparSepto study found that the substitution of paclitaxel with nab-paclitaxel and epicyclophosphamide as a neoadjuvant chemotherapy raised the rate of pathological complete response from 29 percent to 38 percent. A dramatic rise in pCR from 26% to 48 percent was achieved in patients with triple-negative BC. Patients and Methods In the GeparSepto trial patients, there was a 1:1 chance of either nP 125 mg/m2 or P 80 mg/m2 q1w for 12 weeks followed by four cycles of traditionally dosed EC q3w. Patients with HER2+ tumors were prescribed trastuzumab 6mg/kg q3w and perfected with all chemotherapy cycles. At a two-sided significance level of u03b1=0. 05, the log-rank test will have 80% power to show an increase in the 5 year IDFS from 75% to 81. 8%. Result In 69 German centers and 1229 patients, randomly selected to receive either nP or P. For the majority of cycles, a dose of 150 mg/m2 was administered to 179 patients, and at a dose of 125 mg/m2 to 426 patients, nP was recommended. Conclusion As part of an anthracycline/taxane based sequential chemotherapy, patients with nP rather than P was significantly higher pCR rates when patients received nP rather than P. The expected long-term results will help to determine the relative benefit of nP in BC and the surrogate value of pCR for survival endpoints. San Antonio, Texas, In:: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; In:: Proceedings of the San Antonio Breast Cancer Symposium; 2017 Dec 5-9; 2017 Dec 5-9; San Antonio, Texas.

Source link: https://doi.org/10.1158/1538-7445.sabcs17-gs3-05


Abstract CT162: ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)

Abstract Background DLBCL is the most common non-Hodgkin lymphoma in the United Kingdom, accounting for a total number of over 5,000 patients each year. During cycle 1, participants will receive 6 cycles of R-CHOP chemotherapy on a standard 21-day schedule, with the addition of acalabrutinib in cycles 2-6 to enable determination of the subtype by whole transcriptome gene expression profiling during cycle 1. Phase I aims to produce a standardized dose of acalabrutinib in combination with R-CHOP. Duration of response, PFS, and OS, as well as their relationship to the cell of origin subtype, and BTK receptor expression in peripheral blood mononuclear cells and tumor measured by a drug analogue enzyme-linked immunosorbent assay are among the secondary endpoints. In vitro during therapy, the effect of acalabrutinib on antibody-directed cellular cytotoxicity caused by rituximab will be determined. This is an investigator initiated research that has been given free access to investigational medicinal product, trial Analysis, and translational study support through a grant from Acerta Pharma B. V. and has Cancer Research UK support. ISRCTN11965217 Progress Phase I of the study began in April 2017 and has welcomed 6 eligible patients to the first cohort at a dose of 100 mg acalabrutinib once daily, with another four patients admitted to the second cohort receiving a dose of 100 mg acabrutinib twice daily. AcCEPT : Acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone for patients with diffuse large B-cell lymphoma are patients with diffuse large B-cell lymphoma [abstract].

Source link: https://doi.org/10.1158/1538-7445.am2018-ct162


Abstract 3: Metronomic chemotherapy with cyclophosphamide (Cy) and the repositioned drug losartan (Los) for the treatment of M-234p triple negative murine mammary adenocarcinoma

Oncology drug repositioning refers to the use of drugs that have been intended for other indications of antitumor activity. Moreover, TUNEL assay found that a significant rise in apoptosis in GIV vs Control. By flow cytometry, no differences were found among circulating CD4+, CD8+, and Treg cells, although a marginally significant rise in Th17 cells in GII and GIV was observed. The protein u03b1SMA was detected by western blot, giving us some light on the therapy's effect on the cancer-associated fibroblasts of fibroblasts; in GIV vs. GI, the expression of this marker was significantly lower in GIV vs. GI. Mice were released in the same experimental groups on day 3 on day 3. In GII and GIV, the incidence of lung metastasis was significantly lower in the Nu00b0. These results show that metronomic chemotherapy, administered as an intervention technique, can reduce not only the formation of a triple negative mammary adenocarcinoma with permanent declines but also its metastasis, but also its metastasis, but also in the absence of toxicity. Tumor formation, rise of apoptosis, and tumor microenvironment modification can all be achieved, at least partially, by tumor inhibition, rise of apoptosis, and tumor microenvironment modification by tumor fibroblasts. paraphrase mammary adenocarcinoma treated with cyclophosphamide and the repositioned drug losartan in Metronomic chemotherapy for M-234p triple negative murine mammary adenocarcinoma [abstract]. 2018 Apr 14-18; Chicago, Illinois; Proceedings of the American Association for Cancer Research Annual Meeting 2018 (2018-05-18); 2018-04-28; 2018-04-18; The American Association for Cancer Research Annual Meeting; 2018 April 14-18; 2019.

Source link: https://doi.org/10.1158/1538-7445.am2018-3


Abstract 2746: Synergistic immunotherapeutic effects of TLR7/8 agonist on low-dose cyclophosphamide-treated C26 model

Abstract In recent years, low dose cyclophosphamide has been used in clinical trials or as a component therapy to treat lymphomas, breast and ovarian cancers. The aim of this research was to determine whether immunopotentiating TLR7/8 agonists might synergize with low doses of cyclophosphamide in the treatment of colorectal carcinoma. As shown by upregulating IFN-u03b1 gene clusters, systemic immune responses in mice following systemic administration of Resiquimod in mice triggered significant systemic immune responses. The combined therapy of Resiquimod and cyclophosphamide was superior to any single treatment, with improved tumor inhibition and increased longevity, prolonging their survival. Importantly, the combined therapy resulted in significant amounts of tumor-specific T cell infiltration in tumor microenvironment. Our results show that systemic administration of TLR7/8 agonist raises the anti-tumor effects of a low dose of cyclophosphamide.

Source link: https://doi.org/10.1158/1538-7445.am2018-2746


Abstract 1017: Vinorelbine, cyclophosphamide, and 5-FU effects on the circulating and intratumoral landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma

Abstract Checkpoint inhibitors are also effective in various forms of cancer. We investigated the effects of four different doses of three widely used, orally-active chemotherapeutics over local and metastatic tumor formation, as well as the distribution of circulating and tumor-infiltrating immune cells. T cells with circulating CD3+CD4+ and CD3+CD8+ cells in the United Kingdom are particularly vulnerable. Vial reduced NK cells, C and 5-FU were added to circulating NKs, with C and 5-FU increasing circulating NKs. In BC models V, C, and 5-FU were very helpful in reducing local and metastatic tumor formation. In particular B cells, Anti-PD-L1 therapy alone raised BC-infiltrating immune cells, which included B cells. Treatment with C alone resulted in the most significant tumor infiltration by NK, CD3+ T cells, and m-MDSC, as well as the lowest B cell infiltration. With the highest intratumoral B cell count and the fewest number of CD3+PD-1+ T cells, combinedatorial therapy with C+V+anti-PD-L1 was associated with the highest intratumoral B cell count and the lowest number of CD3+PD-1+ T cells. In particular, in B cells, the largest increase in infiltrating immune cells was recorded on a single day, with Anti-PD-L1 alone. The addition of anti-PD-L1 to V and C enhanced B cell infiltrate. These effects on circulating immune cells differ qualitatively and quantitatively from those observed in the intratumoral immune cell infiltrate. Despite the fact that different forms and locations of cancer produce significantly different atlases of intratumoral infiltrates, the present results also indicate that chemotherapy can reduce the effects of CIs. Anti-PD-L1 efficiency in preclinical models of breast cancer and lymphoma, as well as 5-FU effects on the circulating and intratumoral landscape of immune cells [abstract].

Source link: https://doi.org/10.1158/1538-7445.am2018-1017

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions